Skip to Content

Recombitek KC2

This page contains information on Recombitek KC2 for veterinary use.
The information provided typically includes the following:
  • Recombitek KC2 Indications
  • Warnings and cautions for Recombitek KC2
  • Direction and dosage information for Recombitek KC2

Recombitek KC2

This treatment applies to the following species:
Company: Boehringer Ingelheim

Canine Parainfluenza-Bordetella Bronchiseptica Vaccine

Modified Live Virus, Avirulent Live Culture

For Intranasal Use in Dogs Only

For vaccination of healthy, susceptible dogs and puppies as an aid in the prevention of Canine Upper Respiratory Infection (Canine Cough) caused by canine parainfluenza (CPI) and Bordetella bronchiseptica (BB). Field studies support the safety of Recombitek® KC2 when administered to puppies as young as 3 weeks of age.

Description and general information: Recombitek® KC2 is designed to be administered intranasally for convenient, rapid prevention of Canine Upper Respiratory Infection (Canine Cough). Both of these organisms are widespread, common etiologic agents of this syndrome which appears as a mild, self-limiting disease involving the trachea and bronchi of dogs of any age. It spreads rapidly among dogs that are closely confined as in hospitals, kennels and pet stores. The disease is highly contagious and is transmitted via the airborne route.

Both of the organisms in Recombitek KC2 are avirulent so that they can be safely administered intranasally with little or no symptoms of disease. By instilling these organisms into the nasal passages, it becomes possible for these agents to infect target cells of the nasal-pharyngeal region, mimicking the pathogenesis of natural field infection. A very small percentage of dogs may show sneezing, coughing or nasal discharge for 3-10 days following vaccination. While these are usually temporary symptoms, anti-bacterial therapy may be indicated.

Directions and dosage: Rehydrate to desired dose volume with accompanying sterile diluent. For 0.5 mL dose, reconstitute with 0.5 mL diluent. For 1 mL dose, reconstitute with 1 mL diluent. Shake well and use immediately. Using aseptic technique, administer entire dose intranasally. Use enclosed applicator tip on hub of syringe in place of syringe needle. Apply new nasal applicator tip for each dog vaccinated. Do not vaccinate puppies under 3 weeks of age. Puppies vaccinated between 3 and 6 weeks of age should be revaccinated at 6 weeks of age. Historically, annual revaccination with this product has been recommended. The need for annual booster vaccination has not been established for this product. For advice on revaccination frequency, contact your veterinarian or the manufacturer.


For intranasal use in dogs only; do not vaccinate dogs parenterally. Store out of direct sunlight at 35-46°F (2-8°C). Do not freeze. Use entire contents of each container when first opened. Do not mix with other products, except as specified on the label. In case of anaphylactoid reaction, administer epinephrine. This product has not been tested in pregnant animals. In case of human exposure, contact a physician. Inactivate opened containers and unused contents before disposal.

Preservative: Neomycin.

Recombitek® is a registered trademark of Merial.

Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506

Phone: 866-638-2226

VLN/PCN 124/14M1.22

Varied Dose Volume


This package contains 25 (1 dose) vials of dry vaccine, 25 (1 mL) vials of sterile diluent and 25 nasal applicator tips.


CPN: 1028317.0

Telephone:   800-325-9167
Fax:   816-236-2717
Every effort has been made to ensure the accuracy of the Recombitek KC2 information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2020 Animalytix LLC. Updated: 2020-10-21